SS
DYN icon

SBI Securities’s Dyne Therapeutics DYN Stock Holding History

SBI Securities’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42K Sell
154
-5
-3% -$93 ﹤0.01% 2345
2026
Q1 		$2.88K Buy
159
+9
+6% +$155 ﹤0.01% 2280
2025
Q4 		$2.93K Sell
150
-10
-6% -$189 ﹤0.01% 2245
2025
Q3 		$2.02K Buy
160
+61
+62% +$696 ﹤0.01% 2419
2025
Q2 		$942 Buy
99
+30
+43% +$330 ﹤0.01% 2705
2025
Q1 		$722 Buy
69
+50
+263% +$715 ﹤0.01% 2729
2024
Q4 		$448 Buy
+19
New +$562 ﹤0.01% 2934

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SBI Securities's DYN Position: Q2 2026 in Review

SBI Securities reduced its Dyne Therapeutics (DYN) stake by 3.1% in Q2 2026, selling an estimated $93 and leaving 154 shares worth $3.42K. The position accounts for ﹤0.01% of the portfolio, ranked #2345.

SBI Securities first reported a position in DYN in Q4 2024 and has held it in 7 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • SBI Securities held 154 shares of Dyne Therapeutics worth $3.42K as of Q2 2026.
  • SBI Securities sold 5 Dyne Therapeutics shares in Q2 2026, an estimated $93.
  • Dyne Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2345 holding.
  • SBI Securities first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.